Immunotherapy and chemotherapy for advanced throat cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of an immunotherapy drug called penpulimab plus standard chemotherapy for patients with a specific type of throat cancer (hypopharyngeal carcinoma) that is locally advanced but has not spread to other parts of the body. The goal is to see if this combination can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have been diagnosed with locally advanced hypopharyngeal cancer (cancer in the lower throat) that is still removable by surgery.
- The cancer must have spread to lymph nodes in the neck.
- You should not have had previous treatment for advanced disease, though some prior neoadjuvant/adjuvant therapy (given before or after surgery) is allowed if completed at least 6 months ago.
- You must be generally healthy enough for treatment, with adequate organ function (like blood counts, kidney, and liver).
- You must not have active autoimmune disease, prior immunotherapy, or certain other conditions that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (nimotuzumab and toripalimab) with chemotherapy for people with advanced tonsil cancer that can be surgically removed. The goal is to see if this approach works better than standard treatment.
This trial tests whether giving a combination of an immunotherapy drug (PD-1 inhibitor) and chemotherapy before surgery can help treat advanced throat cancer. The goal is to see if this approach shrinks tumors and improves outcomes.
This trial tests giving chemotherapy combined with an immunotherapy drug (finotonlimab) before surgery for locally advanced hypopharyngeal cancer. It aims to shrink the tumor enough to improve surgery outcomes.
This trial tests a new approach to treat throat cancer while trying to preserve your larynx (voice box). It combines chemotherapy drugs and an immunotherapy drug before surgery or radiation. The goal is to see if this can help you avoid needing to have your larynx removed.
This trial tests a new combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery, to shrink the cancer and improve outcomes for patients with advanced hypopharyngeal cancer. It may help make surgery more effective and reduce the chance of the cancer coming back.
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy before surgery improves outcomes for people with advanced laryngeal or hypopharyngeal cancer. The treatment is given before your planned total laryngectomy, and the goal is to shrink the tumor and potentially improve long-term results.
Hear when a new Head & Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.